Large Iranian Study Proves The Potential Of Polypill Concept

Data presented in The Lancet medical journal suggests a polypill fixed-dose combination of aspirin, atorvastatin and hydrochlorothiazide with either enalapril or valsartan could reduce the risk of cardiovascular events significantly. 

Iran_Map
Research conducted in the Golestan province of Iran supports the use of a polypill to reduce cardiovascular risk • Source: Shutterstock

A large-scale study in which more than 3,000 Iranians took ‘polypill’ tablets combining the blood-thinner aspirin, the cholesterol-lowering agent atorvastatin and the diuretic hydrochlorothiazide with either the enalapril or valsartan antihypertensives found that “use of a polypill was effective in preventing major cardiovascular events.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Value Added Medicines

More from Products